Nurix Therapeutics Inc at Credit Suisse Healthcare Conference Transcript
Hey, let's get going. Good afternoon. My name is Rich Law. I'm a senior biotech analyst at CS. I'd like to welcome our next session with Nurix and joining us will be Arthur Sands, President and CEO; and Hans van Houte, CFO. And I think we're going to kick it off with a presentation from you guys. And we'll kick it off on that.
That is correct. Thank you very much, Rich. Let me just stand up so I can look at the big screen too. We will be making certain forward-looking statements so I refer you to our filings with the SEC regarding the risk factors that face our business.
So Nurix, we're a small molecule drug discovery company, we're not oncology. We have four programs in clinical development.
At the center of our drug discovery system at Nurix is the E3 ligase which is pictured here in the center of the screen. It's an enzyme complex system. There are over 600 E3 ligases encoded in the human genome, and these control all
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |